培土生金方药对比H1抗组胺药治疗变应性鼻炎的系统评价与Meta分析

Objective: To evaluate the efficacy and safety of Peitu Shengjin prescription versus H1 antihistamine in the treatment of allergic rhinitis. Methods: Electronic searching "China Knowledge Network", "Wanfang Database", "Vip Database", "Chinese Biomedical Literature Database", PubMed, Embase, The Cochrane Library, all published on the prescription of Peitu Shengjin prescription comparison H1 antihistamine In randomized controlled trials (RCTs) of drug treatment of allergic rhinitis, two researchers screened the literature according to the inclusion and exclusion criteria, and conducted Meta-analysis using RevMan5.3 software. Results: A total of 22 studies were involved, involving a total of 1463 subjects, including 822 in the treatment group and 641 in the control group. Meta-analysis results show that compared with oral H1 antihistamines, Peitu Shengjin prescription can improve the total effective rate of allergic rhinitis (RR=1.19, 95％CI [1.14, 1.24], P<0.00001); reduce recurrence Rate (RR=0.46, 95％ CI [0.23, 0.90], P=0.02); reduce serum IL-6 (MD=-17.33, 95％ CI [-21.96, -12.70], P<0.00001) and serum IL- 8 (MD=-100.35, 95％ CI [-175.18, -25.52], P=0.009); reduce the patient's total score of symptoms and signs (SMD=-1.21, 95％ CI [-1.82, -0.61], P<0.0001) And TCM symptom scores (SMD = -0.98, 95％ CI [-1.28, -0.68], P <0.00001); superior to the control group in improving patients' nasal congestion, nasal itching, and turbinate/nasal mucosa enlargement, in improving runny nose There is no obvious advantage compared with the control group in terms of sneezing symptoms; in terms of safety, there are fewer mild adverse reactions in the treatment group (RD=-0.05, 95％ CI [-0.09, -0.00], P=0.04). Conclusion: Compared with H1 antihistamine, Peitu Shengjin prescription can improve clinical efficacy, improve patients' symptoms and signs and TCM symptoms, regulate immune function, and is not easy to relapse and has good safety.